 |
||
 |
|
|
La technologie UbiScreen est protégée par deux brevets déposés par le laboratoire du Dr. Dominique Thomas pour le CNRS et licenciés à Cytomics Pharmaceuticals (licences exclusives et mondiales). Plusieur brevets protégeant de nouvelles applications et molécules ont été déposés par Cytomics Pharmaceuticals: WO/2009/150248 Compounds which can be used for the treatment of cancers WO/2009/080981 Method for screening for agents that modulate the activity of the Mdm2 ubiquitin ligase and means for implementing said method WO/2007/012724 1,2,4-thiadiazole derivatives antifungal compounds, compositions containing said compounds and the use thereof WO/2007/045799 Method for screening a proteasome activity modulating agent and means for carrying out said method WO/2005/093086 Method for screening agents modulating a IkBa protein ubiquitination and means for carrying out said method
 "Inducible dissociation of SCFMet30 ubiquitin ligase mediates a rapid transcriptional reponse to cadmium" The EMBO Journal 24(3): 521-532 |
|
|
 |
||||||||
     |
||||||||
|
||||||||
     |
||||||||
